| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
C18-Ceramide acts on multiple cellular targets. It promotes glutamate exocytosis in damaged neurons, thereby potentially propagating neuronal damage. It promotes cell death in glioma cells. Ceramides are involved in various cellular functions such as differentiation, cell cycle progression, cell adhesion, senescence, and apoptosis. The compound can cross the blood-brain barrier, making it relevant for neurological research.
|
|---|---|
| ln Vitro |
In vitro, C18-Ceramide promotes glutamate exocytosis in damaged neurons and promotes cell death in glioma cells. Ceramides are involved in various cellular functions including differentiation, cell cycle progression, cell adhesion, senescence, and apoptosis. The compound is a bioactive sphingolipid that modulates cell signaling pathways. However, specific potency data such as IC₅₀ values are not detailed in the available literature.
|
| ln Vivo |
In vivo, C18-Ceramide can cross the blood-brain barrier and is the primary ceramide produced after hippocampal damage. It may promote glutamate exocytosis in damaged neurons, thereby propagating neuronal injury. This suggests it plays a role in the pathophysiology of neurological damage. The compound is an endogenous metabolite involved in normal cellular signaling and apoptosis.
|
| Enzyme Assay |
No specific protocols for enzyme/receptor binding assays are available for C18-Ceramide. As an endogenous sphingolipid, its effects are typically studied in cell-based systems rather than cell-free assays. For studying its role in apoptosis, caspase activity assays can be performed. For studying glutamate exocytosis, neurotransmitter release assays can be employed. However, specific protocols are not detailed.
|
| Cell Assay |
Cellular assays for C18-Ceramide typically involve treating neuronal cells or glioma cells with the compound at concentrations ranging from 1-100 µM for 24-72 hours. Glutamate exocytosis is measured by monitoring neurotransmitter release. Cell death is assessed by MTT or LDH release assays. Apoptosis is evaluated by caspase activity assays and assessment of cell cycle progression. These cell-based systems allow for analysis of the compound's mechanism of action.
|
| Animal Protocol |
In vivo animal experiments for C18-Ceramide are not extensively detailed in the available literature. As the primary ceramide produced after hippocampal damage, it may be studied in animal models of neurological injury. The compound's ability to cross the blood-brain barrier makes it relevant for central nervous system research. However, specific protocols are not available in the consulted sources.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for C18-Ceramide indicate that it can cross the blood-brain barrier. As an endogenous lipid with a molecular weight of 565.95 g/mol, it is a lipophilic molecule that would be expected to have extensive tissue distribution. Ceramides are typically metabolized by ceramidases and other enzymes in the sphingolipid metabolic pathway. However, detailed ADME parameters are not available.
|
| Toxicity/Toxicokinetics |
Toxicological data for C18-Ceramide are limited. As an endogenous sphingolipid, it is a normal component of cellular membranes and is involved in physiological signaling. However, elevated ceramide levels have been associated with apoptosis and cell death. The compound's role in promoting cell death in glioma cells and glutamate exocytosis in damaged neurons suggests it may have pathophysiological roles.
|
| References | |
| Additional Infomation |
N-Octadecanylsphingosine is an N-acylsphingosine in which the N-acyl group of the ceramide is designated as octadecanoyl (stearoyl). It is a mouse metabolite. It is a base of both N-acylsphingosine and N-stearoylsphingosine. It is functionally related to octadecanoic acid. N-stearoylsphingosine has been reported to be detected in Trypanosoma brevicornu, and relevant data are available.
C18-Ceramide (N-stearoyl-D-sphingosine) is an endogenous, long-chain sphingolipid and a crucial component of cellular membranes. It plays significant roles in cell signaling, apoptosis, differentiation, cell cycle progression, cell adhesion, and senescence. The compound can cross the blood-brain barrier and is the primary ceramide produced after hippocampal damage. It promotes glutamate exocytosis in damaged neurons and cell death in glioma cells. It is a research compound and is not approved for any clinical indication. |
| Molecular Formula |
C36H71NO3
|
|---|---|
| Molecular Weight |
565.95
|
| Exact Mass |
565.543
|
| CAS # |
2304-81-6
|
| Related CAS # |
C18-Ceramide-d3;2011762-82-4;C18-Ceramide-d7;1840942-14-4
|
| PubChem CID |
5283565
|
| Appearance |
White to off-white solid powder
|
| Density |
0.915g/cm3
|
| Boiling Point |
694.5ºC at 760 mmHg
|
| Melting Point |
99 - 101ºC
|
| Flash Point |
373.8ºC
|
| Vapour Pressure |
2.59E-22mmHg at 25°C
|
| Index of Refraction |
1.479
|
| LogP |
10.734
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
40
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@@H](/C=C/CCCCCCCCCCCCC)O
|
| InChi Key |
VODZWWMEJITOND-NXCSZAMKSA-N
|
| InChi Code |
InChI=1S/C36H71NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h29,31,34-35,38-39H,3-28,30,32-33H2,1-2H3,(H,37,40)/b31-29+/t34-,35+/m0/s1
|
| Chemical Name |
N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]octadecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7669 mL | 8.8347 mL | 17.6694 mL | |
| 5 mM | 0.3534 mL | 1.7669 mL | 3.5339 mL | |
| 10 mM | 0.1767 mL | 0.8835 mL | 1.7669 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
